Luye Pharma’s Subsidiary Boan Biotech Completes Phase III Trial for Eylea Biosimilar BA9101
Shandong Boan Biotechnology Co., Ltd., a subsidiary of China-based Luye Pharma Group (HKG: 2186), has...
HKG: 2186
Luye Pharma Group Posts 2.7% YOY Revenue Growth in 2023 with Strong Market Performance
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced its...
Luye Pharma Launches Small-Cell Lung Cancer Treatment Zepzelca in Hong Kong and Macau
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the official market launch...
Luye Pharma Initiates Phase III Clinical Trial for Irinotecan Liposome Injection in Small-Cell Lung Cancer
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the enrollment of the...
Luye Pharma Grants Myung In Pharm Rights to Rivastigmine Patch for Alzheimer’s Treatment in South Korea
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced a licensing agreement with...
Luye Pharma’s Paliperidone Palmitate NDA Avoids Patent Lawsuit, Clears Path for FDA Approval
Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced that the New Drug...
Luye Pharma’s Biosimilar Bevacizumab Gets GMP Certification in Brazil
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
Luye Pharma’s Lurbinectedin Receives Market Approval in Hong Kong for SCLC Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that Hong Kong’s pharmacy and poisons board...
Luye Pharma’s Lurbinectedin for Metastatic SCLC Wins Macau Regulatory Nod
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that Macau’s medical products...
AstraZeneca Expands China Presence with Over 30 Agreements at CIIE
At the 6th China International Import Expo (CIIE) in Shanghai, UK-based pharmaceutical giant AstraZeneca plc...
Luye Pharma Group’s Rivastigmine Patch LY03013 Approved by China’s NMPA for Alzheimer’s Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
Luye Pharma Files NDA for Paliperidone Palmitate Injectable Suspension with US FDA
China-based Luye Pharma Group (HKG: 2186) has announced the submission of a New Drug Application...
Luye Pharma’s Botawei Receives NMPA Approval for Breast Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
Luye Pharma Group Reports H1 2023 Revenue Growth with Strong Oncology and CNS Sales
China-based Luye Pharma Group (HKG: 2186) has announced its financial performance for the first half...
Luye Pharma Group’s Subsidiary Boan Biotechnology Reports 18.4% Revenue Growth in H1 2023
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),...
Luye Pharma Group Submits Market Approval Filing for Lurbinectedin in Metastatic SCLC in Macau
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing has been...
Luye Pharma Launches Rykindo in US, a First for Chinese CNS Drug
China-based Luye Pharma Group (HKG: 2186) has announced the official commercial operation of its Rykindo...
Luye Pharma’s Parkinson’s Disease Treatment LY03003 Receives NMPA Review Acceptance
Luye Pharma Group (HKG: 2186) has announced that the National Medical Products Administration (NMPA) has...
Luye Pharma’s Goserelin Acetate Microspheres Approved by NMPA for Prostate Cancer Treatment
Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the...
Luye Pharma’s Lurbinectedin for Metastatic SCLC Accepted for Review by China’s NMPA
China-based Luye Pharma Group (HKG: 2186) has announced that its market filing for lurbinectedin (LY01017)...